Emerging evidence indicates that tumor-killing T cell and anti-PD-L1 antibodies induce ferroptosis in tumor cells, while liproxstatin-1 (a type of highly efficient ferroptosis depressor) inhibits the anticancer efficacy of these agents. This evidence concerns the gene CD274 and neoplasm.